Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer
J Drugs Dermatol. 2024 Apr 1;23(4):e102-e103. doi: 10.36849/JDD.7802.ABSTRACTInflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (MEK) inhibitor agent Trametinib in a woman with ovarian cancer. Biopsies of the scalp were consistent with early scarring alopecia compatible with drug-induced alopecia. Significant improvement in hair loss occurred after treatment with intralesional Kenalog (ILK) injections and oral isotretinoin. Though acute alopecia has been described in patients using ...
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Lucy Rose Abena Minta Jose Plaza David E Cohn Brittany Dulmage Source Type: research
Pilose antler extract promotes hair growth in androgenic alopecia mice by promoting the initial anagen phase
Biomed Pharmacother. 2024 Apr 1;174:116503. doi: 10.1016/j.biopha.2024.116503. Online ahead of print.ABSTRACTAndrogenetic alopecia (AGA) is a prevalent disease in worldwide, local application or oral are often used to treat AGA, however, effective treatments for AGA are currently limited. In this work, we observed the promoting the initial anagen phase effect of pilose antler extract (PAE) on hair regeneration in AGA mice. We found that PAE accelerated hair growth and increased the degree of skin blackness by non-invasive in vivo methods including camera, optical coherence tomography and dermoscopy. Meanwhile, HE staining ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 2, 2024 Category: Drugs & Pharmacology Authors: Menghua Liu Gaiying He Fenglong Wang Yanan Sun Shuhua Ma Yu Hao Yi Wang Source Type: research
Secondary syphilis presenting with alopecia and leukoderma in a stable HIV-positive patient in a resource-limited setting: a case report
CONCLUSION: This case demonstrates the importance of a high index of clinical suspicion and testing for syphilis in patients presenting with atypical clinical features of secondary syphilis, such as hair loss and hypopigmentation. It also highlights the challenges in diagnosing and clinically managing syphilis in a resource-limited setting.PMID:38561779 | PMC:PMC10986119 | DOI:10.1186/s12981-024-00603-w (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - April 2, 2024 Category: Infectious Diseases Authors: Sukoluhle Khumalo Yves Mafulu Victor Williams Normusa Musarapasi Samson Haumba Nkululeko Dube Source Type: research
Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer
J Drugs Dermatol. 2024 Apr 1;23(4):e102-e103. doi: 10.36849/JDD.7802.ABSTRACTInflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (MEK) inhibitor agent Trametinib in a woman with ovarian cancer. Biopsies of the scalp were consistent with early scarring alopecia compatible with drug-induced alopecia. Significant improvement in hair loss occurred after treatment with intralesional Kenalog (ILK) injections and oral isotretinoin. Though acute alopecia has been described in patients using ...
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Lucy Rose Abena Minta Jose Plaza David E Cohn Brittany Dulmage Source Type: research
Secondary syphilis presenting with alopecia and leukoderma in a stable HIV-positive patient in a resource-limited setting: a case report
CONCLUSION: This case demonstrates the importance of a high index of clinical suspicion and testing for syphilis in patients presenting with atypical clinical features of secondary syphilis, such as hair loss and hypopigmentation. It also highlights the challenges in diagnosing and clinically managing syphilis in a resource-limited setting.PMID:38561779 | PMC:PMC10986119 | DOI:10.1186/s12981-024-00603-w (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - April 2, 2024 Category: Infectious Diseases Authors: Sukoluhle Khumalo Yves Mafulu Victor Williams Normusa Musarapasi Samson Haumba Nkululeko Dube Source Type: research
Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer
J Drugs Dermatol. 2024 Apr 1;23(4):e102-e103. doi: 10.36849/JDD.7802.ABSTRACTInflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (MEK) inhibitor agent Trametinib in a woman with ovarian cancer. Biopsies of the scalp were consistent with early scarring alopecia compatible with drug-induced alopecia. Significant improvement in hair loss occurred after treatment with intralesional Kenalog (ILK) injections and oral isotretinoin. Though acute alopecia has been described in patients using ...
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Lucy Rose Abena Minta Jose Plaza David E Cohn Brittany Dulmage Source Type: research
Secondary syphilis presenting with alopecia and leukoderma in a stable HIV-positive patient in a resource-limited setting: a case report
CONCLUSION: This case demonstrates the importance of a high index of clinical suspicion and testing for syphilis in patients presenting with atypical clinical features of secondary syphilis, such as hair loss and hypopigmentation. It also highlights the challenges in diagnosing and clinically managing syphilis in a resource-limited setting.PMID:38561779 | PMC:PMC10986119 | DOI:10.1186/s12981-024-00603-w (Source: AIDS Research and Therapy)
Source: AIDS Research and Therapy - April 2, 2024 Category: Infectious Diseases Authors: Sukoluhle Khumalo Yves Mafulu Victor Williams Normusa Musarapasi Samson Haumba Nkululeko Dube Source Type: research
Mitogen-Activated Protein Kinase Inhibitor-Induced Inflammatory Alopecia in Woman With Ovarian Cancer
J Drugs Dermatol. 2024 Apr 1;23(4):e102-e103. doi: 10.36849/JDD.7802.ABSTRACTInflammatory alopecia is an increasingly reported side effect of targeted cancer therapies. Here we report one case of inflammatory alopecia secondary to mitogen-activated protein kinase kinase (MEK) inhibitor agent Trametinib in a woman with ovarian cancer. Biopsies of the scalp were consistent with early scarring alopecia compatible with drug-induced alopecia. Significant improvement in hair loss occurred after treatment with intralesional Kenalog (ILK) injections and oral isotretinoin. Though acute alopecia has been described in patients using ...
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Lucy Rose Abena Minta Jose Plaza David E Cohn Brittany Dulmage Source Type: research
